The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus

Annual Review of Microbiology

Volumn 56, Issue , 2002, Pages 657-675

  Walsh, Timothy R ^a   Howe, Robin A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Glycopeptide resistance; hVISA; VISA

Indexed keywords

BETA LACTAM ANTIBIOTIC; PEPTIDOGLYCAN; TEICOPLANIN; VANCOMYCIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL MUTATION; CELL METABOLISM; GENE EXPRESSION REGULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; MUTATION; PREVALENCE; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0036403740     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.56.012302.160806     Document Type: Review

References (75)

1. Anderson JS, Matsuhashi M, Haskin MA, Strominger JL. 1967. Biosythesis of the peptidoglycan of bacterial cell walls. II. Phospholipid carriers in the reaction sequence. J. Biol. Chem. 242:3180-90
2. Aritaka N, Hanaki H, Cui L, Hiramatsu K. 2001. Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob. Agents Chemother. 45:1292-94
3. Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, et al. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-88
4. Arvidson SK, Tegmark K. 2001. Regulation of virulence determinants in Staphylococcus aureus. Int. J. Med. Microbiol. 291:159-70
5. Aucken HM, Warner M, Ganner M, Johnson AP, Richardson JF, et al. 2000. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 46:639-40
6. Avison MB, Bennett PM, Howe RA, Walsh TR. 2002. Preliminary analysis of the genetic basis for vancomcyin resistance in Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother. 49:255-60
7. Ayliffe GA. 1997. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 24 (Suppl. 1):S74-79
8. Bayer MG, Heinrichs JH, Cheung AL. 1996. The molecular architecture of the sar locus in Staphylococcus aureus. J. Bacteriol. 178:4563-70
9. Biavasco F, Giovanetti E, Montanari, MP, Lupidi R, Varaldo PE. 1991. Development of in-vitro resistance to glycopeptide antibiotics: Assessment in staphylococci of different species. J. Antimicrob. Chemother. 27:71-79
10. Bobin-Dubreux S, Reverdy ME, Nervi C, Rougier M, Bolmstrom A, et al. 2001. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob. Agents Chemother. 45:349-52
11. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-77
12. Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RS. 2001. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 45:280-87
13. Bruckner R, Bassias J. 2000. Carbohydrate catabolism pathways and regulation in Staphylococci. In Gram Positive Pathogens, ed. VA Fiscetti, RP Novick, JJ Ferretti, DA Portnoy, JI Rood. pp. 339-44. Washington, DC: ASM Press
14. Canton R, Mir N, Martinez-Ferrer M, Sanchez del Saz B, Soler I, Baquero F. 1999. Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides. Rev. Esp. Quim. 12:48-53
15. Chatterjee AN, Perkins HR. 1966. Compounds formed between nucleotides related to the biosynthesis of bacterial cell wall and vancomycin. Biochem. Biophys. Res. Commun. 24:489-94
16. Chesneau O, Morvan A, Solh NE. 2000. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J. Antimicrob. Chemother. 45:887-90
17. Cheung AL, Schmidt K, Bateman B, Manna AC. 2001. SarS, a SarA homolog repressible by agr, is an activator of protein A synthesis in Staphylococcus aureus. Infect. Immun. 69:2448-55
18. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. 2000. Contribution of a thickened cell wall and its glutamine non-amidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-85
19. Daum RS, Gupta S, Sabbagh R, Milewski WM. 1992. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility. J. Infect. Dis. 166:1066-72
20. Domanski TL, de Jonge BL, Bayles KW. 1997. Transcription analysis of the Staphylococcus aureus gene encoding penicillin-binding protein 4. J. Bacteriol. 179:2651-57
21. Fairbrother RW, Williams BL. 1956. Two new antibiotics: Antibacterial activity of novobiocin and vancomycin. Lancet:1177-78
22. Finan JE, Archer GL, Pucci MJ, Climo MW. 2001. Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:3070-75
23. Fridkin SK, Hageman JC, McDougal L, Mohammed J, Kellum ME, et al. 2001. Nationwide epidemiologic study of Staphylococcus aureus with reduced susceptibility to vancomycin. 41st Intersci. Confer. Antimicrobial Agents and Chemotherapy. Chicago: ASM
24. Garrod LP, Waterworth PM. 1956. Behaviour in vitro of some new antistaphylococcal antibiotics. Br. Med. J.:61-65
25. Geisel R, Schmitz FJ, Thomas L, Berns G, Zetsche O, et al. 1999. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J. Antimicrob. Chemother. 43:846-48
26. Hanaki H, Inaba Y, Sasaki K, Hiramatsu K. 1998. A novel method of detecting Staphylococcus aureus heterogeneously resistant to vancomycin (hetero-VRSA). Jpn. J. Antibiot. 51:521-30
27. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K. 1998. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother. 42:315-20
28. Henze UU, Berger-Bachi B. 1995. Staphylococcus aureus penicillin-binding protein 4 and intrinsic beta-lactam resistance. Antimicrob. Agents Chemother. 39:2415-22
29. Henze UU, Berger-Bachi B. 1996. Penicillin-binding protein 4 overproduction increases beta-lactam resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:2121-25
30. Heyer G, Saba S, Adarno R, Rush W, Soong G, et al. 2002. Staphylococcus aureus agr and sarA functions are required for invasive infection but not inflammatory responses in the lung. Infect. Immun. 70:127-33
31. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-73
32. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-36
33. Howe RA, Wootton M, Bennett PM, MacGowan AP, Walsh TR. 1999. Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility. J. Clin. Microbiol. 37:3068-71
34. Hubert SK, Mohammed JM, Fridkin SK, Gaynes RP, McGowan JE, Tenover FC. 1999. Glycopeptide-intermediate Staphylococcus aureus: Evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J. Clin. Microbiol. 37:3590-93
35. Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, et al. 2001. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39:4445-51
36. Imada A, Nozaki Y, Kawashima F, Yoneda M. 1977. Regulation of glucosamine utilization in Staphylococcus aureus and Escherichia coli. J. Gen. Microbiol. 100:329-37
37. Jiang P, Peliska JA, Ninfa AJ. 1998. The regulation of Escherichia coli glutamine synthetase revisited: Role of 2-ketoglutarate in the regulation of glutamine synthetase adenylylation state. Biochemistry 37:12802-10
38. Jung SI, Kiem S, Lee NY, Kim YS, Oh WS, et al. 2002. One-point population analysis and effect of osmolarity on detection of hetero-vancomycin-resistant Staphylococcus aureus. J. Clin. Microbiol. 40:1493-95
39. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. 1990. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J. Infect. Dis. 162:103-8
40. Kuroda M, Kuwahara-Arai K, Hiramatsu K. 2000. Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem. Biophys. Res. Commun. 269:485-90
41. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, et al. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:1225-40
42. Linnett PE, Strominger JL. 1974. Amidation and cross-linking of the enzymatically synthesized peptidoglycan of Bacillus stearothermophilus. J. Biol. Chem. 249:2489-96
43. Lowy FD. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-30
44. Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC. 2000. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J. Clin. Microbiol. 38:866-69
45. Marlowe EM, Cohen MD, Hindler JF, Ward KW, Bruckner DA. 2001. Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: A tertiary-care hospital laboratory's experience. J. Clin. Microbiol. 39:2637-39
46. Nakel M, Ghuysen JM, Kandler O. 1971. Wall peptidoglycan in Aerococcus viridans strains 201 Evans and ATCC 11563 and in Gaffkya homari strain ATCC 10400. Biochemistry 10:2170-75
47. Navarre WW, Schneewind O. 1999. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol. Mol. Biol. Rev. 63:174-229
48. Noble WC, Virani Z, Cree RG. 1992. Cotransfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 72:195-98
49. Oliveira GA, Dell'Aquila AM, Masiero RL, Levy CE, Gomes MS, et al. 2001. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect. Control Hosp. Epidemiol. 22:443-58
50. Pfeltz RF, Singh VK, Schmidt JL, Batten MA, Baranyk CS, et al. 2000. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob. Agents Chemother. 44:294-303
51. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212
52. Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, et al. 1999. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. 5:147-49
53. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L, et al. 2001. Characterisation of the accessory gene regulator (agr) locus in geographically diverse Staphylcoccus aureus with reduced susceptibility to vancomycin. 41st Intersci. Conf. Antimicrobial Agents and Chemotherapy. Chicago: ASM
54. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L, et al. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-502
55. Schrader-Fischer G, Berger-Bachi B. 2001. The AbcA transporter of Staphylococcus aureus affects cell autolysis. Antimicrob. Agents Chemother. 45:407-12
56. Sieradzki K, Pinho MG, Tomasz A. 1999. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J. Biol. Chem. 274:18942-46
57. Sieradzki K, Roberts RB, Haber SW, Tomasz A. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340:517-23
58. Sieradzki K, Tomasz A. 1996. A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus. FEMS Microbiol. Lett. 142:161-66
59. Sieradzki K, Tomasz A. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-66
60. Sieradzki K, Tomasz A. 1998. Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis. Microb. Drug Resist. 4:159-68
61. Sieradzki K, Tomasz A. 1999. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J. Bacteriol. 181:7566-70
62. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus working group. N. Engl. J. Med. 340:493-501
63. Tenover FC, Biddle JW, Lancaster MV. 2001. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7:327-32
64. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, et al. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-27. Erratum. 1998. J. Clin. Microbiol. 36(7):2167
65. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, et al. 2001. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J. Clin. Microbiol. 39:591-95
66. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, et al. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-44
67. Walsh TR, Wootton M, Howe RA, Bennett PM, MacGowan AP. 1999. Increased biofilm formation and adherence to artificial surfaces of hVISA [heterogeneous vancomycin (V) intermediate Staphylococcus aureus] on exposure to vancomcyin. 39th Intersci. Conf. Antimicrob. Agents Chemother. San Fransisco: ASM
68. Ward PB, Johnson PD, Grabsch EA, Mayall BC, Grayson ML. 2001. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med. J. Aust. 175:480-83
69. Watanakunakorn C. 1990. In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin. J. Antimicrob. Chemother. 25:69-72
70. Wilcox MH, Fawley W. 2001. Extremely low prevalence of UK Staphylococcus aureus isolates with reduced susceptibility to vancomycin. J. Antimicrob. Chemother. 48:144-45
71. Williams I, Venables WA, Lloyd D, Paul F, Critchley I. 1997. The effects of adherence to silicone surfaces on antibiotic susceptibility in Staphylococcus aureus. Microbiology 143 (Pt. 7):2407-13
72. Wong SS, Ho PL, Woo PC, Yuen KY. 1999. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin. Infect. Dis. 29:760-67
73. Woodford N, Warner M, Aucken HM. 2000. Vancomycin resistance among epidemic strains of methicillin-resistant Staphylococcus aureus in England and Wales. J. Antimicrob. Chemother. 45:258-59
74. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403
75. Wyke AW, Ward JB, Hayes MV, Curtis NA. 1981. A role in vivo for penicillin-binding protein-4 of Staphylococcus aureus. Eur. J. Biochem. 119:389-93